R&D Strategies for creating an ecosystem to support early-stage ... Learn how to foster growth for early-stage biotech companies through innovative ecosystem strategies and valuable CDMO collaborations
Digital Garbage in, garbage out: The hidden data crisis in pharma This hidden data crisis is the fundamental barrier to scaling AI in the life sciences sector.
Digital Consolidating Digital Health: Insights from Frontiers Health... Rob Milnes (Ultrahuman) connected with pharmaphorum off the Frontiers Health stage to share some insights.
Market Access Medical start-ups must address the evolving risks of the FDA... Embarking on the journey of a medical start-up is like navigating a complex labyrinth, where the final prize is the coveted FDA approval.
R&D How pharma companies can build mutually beneficial relations... Seemingly every week, headlines declare new partnerships inked between global pharma giants and previously unknown start-ups.
Market Access Which companies will last? Success begins with the basics Founding a new company is a high stakes business. Many leaders begin with an exciting, well-funded solution and then struggle to build a sustainable business over time.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.